Page 2 - Zydus Lifesciences Ltd News

Zydus Life Q3 result: Profit up marginally at ₹1,042 cr, revenue jumps 32%

Zydus Life Q3 Ebitda for the quarter was ₹1,816.4 crore, up 31 per cent Y-o-Y. Ebitda margin during the same period stood at 26.5 per cent, marking an improvement of 20 basis points

Q3 results: Pfizer, Zydus Lifesciences, Aurobindo Pharma, 181 more on Feb 9

Q3FY26 company results: Firms including GlaxoSmithKline Pharmaceuticals, The Ramco Cements, Linde India, Gulf Oil Lubricants, and Bata India are also to release their October-December earnings today

Zydus receives orphan drug status for Sickle Cell Disease medication

Zydus Lifesciences on Friday said the US health regulator has granted Orphan Drug Designation to Desidustat, a novel oral product medication for the treatment of Sickle Cell Disease. The US Food and Drugs Administration's (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease. We believe that Desidustat can address this unmet need," Zydus Lifesciences MD Sharvil Patel said in a statement. Therapeutic options for management of Sickle Cell Disease are currently limited. A Phase II, double blind, randomised, placebo controlled, parallel, multi-centre, proof-of-concept study to evaluate the efficacy and safety of Desidustat oral tablet for treatment of SCD has been completed, and data will be published in a medical journal, the drug firm said. Orphan drug designation by

Zydus Lifesciences gets US FDA approval for generic diabetes drug

Zydus Lifesciences on Wednesday has received approval from the US health regulator to market a generic diabetes drug in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Dapagliflozin Tablets in strengths of 5 mg and 10 mg, the drug firm said in a statement. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. The company said the tablets will be manufactured at its formulation manufacturing facility at SEZ, Ahmedabad. As per the industry estimates, Dapagliflozin tablets had annual sales of USD 10,486.9 million in the US. Zydus shares on Wednesday ended 0.23 per cent up at Rs 905 apiece on BSE.

Zydus Lifesciences launches cancer drug Nivolumab's biosimilar in India

Move comes just months before nivolumab patent expiry in India on May 2, 2026

Zydus Lifesciences upgraded to 'Buy' at Systematix; check target here

Systematix said the recent US FDA approval of Zycubo, a Menkes disease treatment marketed by Sentynl Therapeutics, significantly enhances the company's growth outlook

Delhi High Court allows Zydus to sell generic version of cancer drug

The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing the firm to maintain audited sales accounts pending the patent case